Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials supported as of March 31, 2024 § $242 - $252 million full year 2024 revenue guidance reiterated NASHVILLE, Tennessee, May 7, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life scienc ...